<div>

3 February 2012 - US diabetes and cancer therapies developer MannKind Corp (NASDAQ:MNKD) said on Thursday it had priced its underwritten public offering of units bundling common shares and warrants for estimated gross proceeds of USD75m (EUR57m).

The company is selling ...

 

 

 

You must be logged in to view the whole article.
Click here if you require signing up